JP2017513908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513908A5 JP2017513908A5 JP2016564236A JP2016564236A JP2017513908A5 JP 2017513908 A5 JP2017513908 A5 JP 2017513908A5 JP 2016564236 A JP2016564236 A JP 2016564236A JP 2016564236 A JP2016564236 A JP 2016564236A JP 2017513908 A5 JP2017513908 A5 JP 2017513908A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- ros1
- pharmaceutically acceptable
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461984599P | 2014-04-25 | 2014-04-25 | |
| US61/984,599 | 2014-04-25 | ||
| PCT/US2015/027800 WO2015164869A1 (en) | 2014-04-25 | 2015-04-27 | Method of treating lung adenocarcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019126230A Division JP2019189646A (ja) | 2014-04-25 | 2019-07-05 | 肺腺癌の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513908A JP2017513908A (ja) | 2017-06-01 |
| JP2017513908A5 true JP2017513908A5 (https=) | 2018-06-14 |
| JP6696908B2 JP6696908B2 (ja) | 2020-05-20 |
Family
ID=53055132
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564236A Active JP6696908B2 (ja) | 2014-04-25 | 2015-04-27 | 肺腺癌の治療方法 |
| JP2019126230A Pending JP2019189646A (ja) | 2014-04-25 | 2019-07-05 | 肺腺癌の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019126230A Pending JP2019189646A (ja) | 2014-04-25 | 2019-07-05 | 肺腺癌の治療方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20170042880A1 (https=) |
| EP (2) | EP3906921A1 (https=) |
| JP (2) | JP6696908B2 (https=) |
| KR (1) | KR102474701B1 (https=) |
| CN (1) | CN106488768A (https=) |
| AR (1) | AR100191A1 (https=) |
| AU (1) | AU2015249232B2 (https=) |
| BR (1) | BR112016024672A2 (https=) |
| CA (1) | CA2946416C (https=) |
| DK (1) | DK3134084T3 (https=) |
| EA (1) | EA035223B1 (https=) |
| ES (1) | ES2874875T3 (https=) |
| HU (1) | HUE054557T2 (https=) |
| IL (1) | IL248408B (https=) |
| MX (1) | MX375716B (https=) |
| PL (1) | PL3134084T3 (https=) |
| PT (1) | PT3134084T (https=) |
| SG (1) | SG11201608657QA (https=) |
| TW (1) | TWI724988B (https=) |
| UA (1) | UA121655C2 (https=) |
| WO (1) | WO2015164869A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140025496A (ko) | 2011-05-02 | 2014-03-04 | 엑셀리시스, 인코포레이티드 | 암 및 뼈 암 통증의 치료방법 |
| EA201691850A1 (ru) | 2014-03-17 | 2016-12-30 | Экселиксис, Инк. | Дозирование составов, содержащих кабозантиниб |
| ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
| BR112017002318A2 (pt) | 2014-08-05 | 2018-07-17 | Exelixis, Inc. | combinações de fármacos para tratar mieloma múltiplo. |
| RU2748549C2 (ru) | 2016-04-15 | 2021-05-26 | Экселиксис, Инк. | Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата |
| CN107353246A (zh) * | 2016-12-27 | 2017-11-17 | 辅仁药业集团熙德隆肿瘤药品有限公司 | 一种制备抗肿瘤药物卡博替尼的方法 |
| CA3059119C (en) * | 2017-05-31 | 2024-01-23 | F. Hoffman-La Roche Ag | Multiplex pcr detection of alk, ret, and ros fusions |
| EP3634413A1 (en) | 2017-06-09 | 2020-04-15 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
| CN107541550A (zh) * | 2017-08-21 | 2018-01-05 | 上海派森诺生物科技股份有限公司 | 人ros1融合基因检测方法 |
| EP3685166A2 (en) * | 2017-09-20 | 2020-07-29 | Mersana Therapeutics, Inc. | Compositions and methods for predicting response to napi2b-targeted therapy |
| MA51679A (fr) * | 2018-01-26 | 2020-12-02 | Exelixis Inc | Composés destinés au traitement de troubles dépendant de la kinase |
| UA128476C2 (uk) | 2018-01-26 | 2024-07-24 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| UA128348C2 (uk) | 2018-01-26 | 2024-06-19 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| AR119069A1 (es) * | 2019-06-04 | 2021-11-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de quinasas |
| DE102020005002A1 (de) * | 2020-08-17 | 2022-02-17 | Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh | Mittel zur Therapie von Tumorerkrankungen |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5756696A (en) | 1986-01-16 | 1998-05-26 | Regents Of The University Of California | Compositions for chromosome-specific staining |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US5491224A (en) | 1990-09-20 | 1996-02-13 | Bittner; Michael L. | Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| US20100143918A1 (en) | 2007-01-19 | 2010-06-10 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
| WO2009051846A2 (en) | 2007-10-18 | 2009-04-23 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
| WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
| SG173014A1 (en) * | 2009-01-16 | 2011-08-29 | Exelixis Inc | Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
| AU2010213578B2 (en) | 2009-02-12 | 2015-01-29 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
| TWI585088B (zh) * | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| CN114129566A (zh) * | 2012-09-07 | 2022-03-04 | 埃克塞里艾克西斯公司 | 用于治疗肺腺癌的met、vegfr和ret的抑制剂 |
-
2015
- 2015-04-27 IL IL248408A patent/IL248408B/en unknown
- 2015-04-27 EA EA201692150A patent/EA035223B1/ru not_active IP Right Cessation
- 2015-04-27 PT PT157211004T patent/PT3134084T/pt unknown
- 2015-04-27 HU HUE15721100A patent/HUE054557T2/hu unknown
- 2015-04-27 EP EP21162169.3A patent/EP3906921A1/en not_active Withdrawn
- 2015-04-27 JP JP2016564236A patent/JP6696908B2/ja active Active
- 2015-04-27 MX MX2016013600A patent/MX375716B/es active IP Right Grant
- 2015-04-27 AU AU2015249232A patent/AU2015249232B2/en active Active
- 2015-04-27 CN CN201580022580.7A patent/CN106488768A/zh active Pending
- 2015-04-27 US US15/305,854 patent/US20170042880A1/en not_active Abandoned
- 2015-04-27 SG SG11201608657QA patent/SG11201608657QA/en unknown
- 2015-04-27 AR ARP150101255A patent/AR100191A1/es unknown
- 2015-04-27 EP EP15721100.4A patent/EP3134084B1/en not_active Revoked
- 2015-04-27 KR KR1020167033010A patent/KR102474701B1/ko active Active
- 2015-04-27 ES ES15721100T patent/ES2874875T3/es active Active
- 2015-04-27 TW TW104113427A patent/TWI724988B/zh active
- 2015-04-27 CA CA2946416A patent/CA2946416C/en active Active
- 2015-04-27 UA UAA201611881A patent/UA121655C2/uk unknown
- 2015-04-27 BR BR112016024672-1A patent/BR112016024672A2/pt not_active Application Discontinuation
- 2015-04-27 WO PCT/US2015/027800 patent/WO2015164869A1/en not_active Ceased
- 2015-04-27 DK DK15721100.4T patent/DK3134084T3/da active
- 2015-04-27 PL PL15721100T patent/PL3134084T3/pl unknown
-
2019
- 2019-07-05 JP JP2019126230A patent/JP2019189646A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513908A5 (https=) | ||
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| RU2018109902A (ru) | Виды комбинированной терапии для лечения рака | |
| JP2013526843A5 (https=) | ||
| KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
| Song et al. | Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress | |
| EA201500373A1 (ru) | Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор | |
| RU2017119066A (ru) | Композии апилимода и способы их применения в лечении колоректального рака | |
| JP2019512020A5 (https=) | ||
| JP2017519006A5 (https=) | ||
| JP6532478B2 (ja) | 血液悪性腫瘍を処置するための方法および材料 | |
| RU2017146346A (ru) | Комбинированная терапия pac-1 | |
| US20250319186A1 (en) | Treatment of canine cancers | |
| Lu et al. | Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study | |
| TWI804333B (zh) | 醫藥組合物治療肺癌之用途 | |
| CN110840892A (zh) | 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途 | |
| Nelson et al. | Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer | |
| JP2014525270A5 (https=) | ||
| RU2014123166A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| WO2024246868A1 (en) | Methods of using alternating electric fields and checkpoint inhibitors | |
| US20230332243A1 (en) | Patient selection biomarkers for treatment with ulk inhibitors | |
| Karavasilis | Small cell lung cancer: current and future strategies | |
| KR20200110452A (ko) | 담도암을 치료하기 위한 방법 및 조합 요법 | |
| RU2014110271A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| Qianqi et al. | Efficacy and safety of transarterial infusion of anti-PD-1 in the treatment of advanced or metastatic acral and mucosal melanomas |